<DOC>
	<DOCNO>NCT00984503</DOCNO>
	<brief_summary>The purpose study investigate accelerated-healing potential injection injection plus topical application Juvista minor split skin graft ( SSG ) .</brief_summary>
	<brief_title>Investigation Accelerated Healing Anti-scarring Potential Avotermin ( Juvista ) Split Skin Graft Donor Sites</brief_title>
	<detailed_description>Subjects allocate three group ( Group 1 , Group 2 Group 3 ) subject receive two 3cm2 SSG donor site , one side low back . Before wound Day 0 , site randomise receive either intradermal injection Juvista ( 50ng/100μl/cm2 ) , intradermal injection Placebo ( 100μl/cm2 ) injection ( Standard Care ) . After wound , subject allocate Group 2 Group 3 also receive topical Juvista ( 100ng/200μl/cm2 ) , topical Placebo ( 200μl/cm2 ) Standard Care ( Tegaderm dress ) . Topical Juvista Placebo hold within Granuflex ring dress seal sterile Tegaderm dressing . On Day 1 , subject Group 2 Group 3 receive topical application Juvista , Placebo Standard Care accord treatment randomisation Day 0 . Punch biopsy sample heal SSG donor site harvest Group 3 subject Day 3 , 5 , 7 10 , preserve histological analysis . The final study visit Group 3 subject day biopsy visit . Subjects Group 1 Group 2 underwent scar assessment first follow-up Month 1 Months 2 , 3 , 4 , 5 , 6 , 9 12 .</detailed_description>
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Clinically healthy , male subject age 1885 year Weight 40 150kg BMI within permitted range height use Quetelet 's index , 1555 kg/m2 . Weight ( kg ) /height ( ) 2 . Subjects history evidence hypertrophic keloid scar tattoos previous scar area prospective SSG donor sit Subjects receive surgery area lower back/buttocks previous 12 month AfroCaribbean subject exclude increased susceptibility hypertrophic keloid scar Subjects evidence past present clinically significant disease , particularly coagulation disorder , diabetes , immunomediated condition , skin disease allergy ( clinically significant eczema Subjects history clinically significant allergy , especially drug hypersensitivity lignocaine , allergy surgical dressing use trial excipients vehicle formulation delivery vehicle Subjects clinically significant abnormality follow review pretrial laboratory data physical examination Subjects receive receive certain prescribed drug 4 week prior Day 0 , particularly topical systemic steroid , anti inflammatory , anticoagulant , antiproliferative drug antibiotic . Certain drug exclude trial include overthecounter analgesic , include paracetamol codeine , vitamin mineral supplement , cold remedy . If antibiotic require Day 0 ( e.g. , case wound infection ) , result exclusion affect subject study Subjects take part clinical trial within 3 month prior admission trial currently participate clinical trial , whether investigational drug use . Subjects clinical evidence severe ongoing prolonged depression mental illness Subjects smoke 20 cigarette day Subjects drink 28 unit alcohol per week ( 1 unit = ½ pint beer [ 285ml ] , 25ml spirit 1 glass wine ) Subjects demonstrate evidence drug abuse Subjects know serum hepatitis carrier hepatitis B surface antigen hepatitis C antibody ( Subjects previous vaccination hepatitis B exclude per se ) Subjects know , , serum hepatitis carrier hepatitis B core antibody le 10 unit per litre antihepatitis B ( unless deem NOT carrier hepatitis B test Public Health Laboratory ) Subjects previously test positive HIV antibody admit belong highrisk group A subject , opinion Investigator , unlikely complete trial whatever reason</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cicatrix</keyword>
	<keyword>Scar</keyword>
	<keyword>Wound heal</keyword>
	<keyword>Avotermin</keyword>
	<keyword>TGF beta 3</keyword>
	<keyword>Juvista</keyword>
	<keyword>RN1001</keyword>
</DOC>